SBC Medical Group Holdings (SBC) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
11 Jun, 2026Company overview and key figures
Provides consulting and management services to medical corporations and clinics, operating the largest franchised clinic network in Japan and a leading position in the aesthetic medical industry.
Operates 166 clinics in Japan and 2 overseas, with $193mn revenue, $82mn EBITDA, $39mn net income, and 32% ROE in FY2023.
Achieved a 15% five-year CAGR in clinic numbers and a 71% customer repeat rate, serving 3.9 million annual customers.
Business model and services
Operates a franchise model, providing consulting, management, marketing, procurement, and equipment leasing services to clinics.
Franchise network covers diverse specialties: dermatology, aesthetic surgery, dentistry, hair removal, fertility, orthopedics, and more.
Offers a fully digitized integrated system for clinic operations, enhancing efficiency and customer experience.
Market position and growth
Holds a leading 31% market share among medium to large aesthetic clinic groups in Japan, with significant expansion after adding Rize and Gorilla Clinics.
Five-year revenue CAGR of 24%, with revenue rising from $459mn in 2018 to $1.1bn in 2023 for franchisees.
Market penetration remains low (10%), with growth potential targeting middle-aged women and men, and expansion into dermatology.
Latest events from SBC Medical Group Holdings
- Underlying growth, AI-driven efficiency, and longevity-focused expansion drive future prospects.SBC
Sidoti Small-Cap Virtual Investor Conference18 Jun 2026 - AI-driven, multi-brand healthcare model targets global expansion and double-digit growth.SBC
Emerging Growth Conference 9311 Jun 2026 - Scalable clinic network drives growth with data-driven efficiency and a focus on longevity.SBC
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference3 Jun 2026 - Key votes include director elections, auditor ratification, and major governance amendments.SBC
Proxy filing28 May 2026 - Shareholders will vote on director elections, auditor ratification, and major charter amendments.SBC
Proxy filing28 May 2026 - Shareholders will vote on director elections, auditor ratification, and major charter amendments.SBC
Proxy filing15 May 2026 - Q1 2026 revenue and net income declined, but underlying growth and liquidity remained strong.SBC
Q1 202614 May 2026 - Net income and EPS rose in 2025 despite revenue declines, with growth expected in 2026.SBC
Q4 20257 Apr 2026 - Scalable multi-brand medical group achieves rapid global growth and high customer retention.SBC
Corporate presentation27 Mar 2026